• UltraPlay provides turn-key platform to reach growing global audience.
• Esports is now a necessity for gambling operators.
• Success in eSports lies in ability to pivot, continually improve player experience, and build brand loyalty.

Mobius Interactive, an online gaming operator, has partnered with the multi award-winning betting provider UltraPlay (https://ibn.fm/dzMDK). This partnership equips Mobius to provide players with access to more than 34 eSports games, live events and mystery jackpots, as well as live and prematch odds. In September 2020, Mobius launched its initial three brands with UltraPlay; this expanded partnership will equip the company to further enhance the player experience in eSports and move forward into new regions worldwide. UltraPlay provides Mobius with cutting-edge technology and a wide range of functionalities. With its focus on sports and eSports betting, live betting, white-label and online casinos, UltraPlay was the natural choice for a turn-key platform to reach an ever-growing global audience. “We are a team of gamers at heart,” said Mobius CEO Lynn Pearce, “so when it came to deciding which eSports iGaming platform provider to partner with when launching our company, it was a no-brainer for us. We knew immediately that we wanted to partner with the multiple esports award-winning UltraPlay.” CEO Mario Ovcharov noted UltraPlay’s excitement for the new partnership as well. “Being [Mobius’s] first-choice iGaming platform provider is great recognition for the entire team of UltraPlay,” Ovcharov said. “What’s even more exciting to us is their enthusiasm and commitment to the eSports betting sector.” According to the Esports Insider, esports is no longer an accessory for gambling operators but rather a necessity (https://ibn.fm/xi1zb). While brick-and-mortar casinos and live sporting events have closed due to social distance restrictions, eSports could pivot to a fully online structure. The global eSports market is expected to reach a value of $3 billion by 2025, following its immense growth in 2020. If current trends hold, 2021 is expected to see a 10% increase in growth. This is largely due to betting operators, such as Mobius, continually improving their products and building brand loyalty (https://ibn.fm/J3Y6D). The partnership between UltraPlay and Mobius is a natural fit, one that will only improve the player experience. The iGaming professionals at UltraPlay combined with the eSports and Casino industry experts at Mobius make it possible to provide a constantly evolving, fully interactive player experience that is customer centric and endlessly entertaining under the Mobius Brand. “We strongly believe that together,” said Ovcharov, “we could further enhance the player experience in a very dynamic sector such as eSports.” Mobius provides players with access to more than 34 eSports games and mega tournaments. Available around the clock, the platform has a wide range of functionalities, mystery jackpots, cutting-edge technology, and live and prematch odds. The company has partnered with UltraPlay, a globally recognized, award-winning, unrivaled eSports odds and platform supplier. The esSports industry is booming, and Mobius is ideally positioned to see the greatest benefit from the boom. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• The global COVID pandemic, community violence and political strife have all served to batter the national psyche during the past year
• Journalists and researchers have reported rising levels of depression and anxiety as well as a rising number of people experiencing property and violent crime
• Knightscope is a company dedicated to building and marketing autonomous security robots (“ASRs”) as a means of helping to make the United States safer
• Knightscope’s ASR series comes in different models that function from a stationary base or a mobile sentry, serving as a deterrent by 24/7 presence and the technological capability to monitor, record and transmit various data streams
• Mordor Intelligence analysts forecast a favorable market for ASRs, growing at a CAGR of 7.93 percent through 2026 to a $3.91 billion market

Following a year headlined by the impositions of a deadly worldwide pandemic, community violence attributed to racial unrest and national upheaval over political strife, it comes as no surprise that researchers are reporting skyrocketing levels of anxiety and depression and feelings of insecurity in the United States (https://ibn.fm/j4QbO). Home security journalists at SafeWise noted in their second annual State of Safety report last year that 40 percent of respondents throughout the country said they’d had a personal experience with property or violent crime during the previous 12 months, a 73 percent increase over responses in 2019. Broken down between the two categories, there was a 50 percent increase in reports of experiencing violent crime and an 86 percent increase in experiencing property crime (https://ibn.fm/2jfVR). In a virtual fireside interview with IPO Edge recently, security robot innovator Knightscope CEO William Santana Li said his company’s efforts to deploy fleets of autonomous sentries in parks, parking lots and other client perimeters amounts to a personal mission to “make the United States of America the safest country in the world” (https://ibn.fm/XzaeT). In order to accomplish that goal, Knightscope has developed K series autonomous security robots (“ASRs”) that can detect and monitor a variety of information sources, whether that involves facial recognition features, license plate detection, broadcast frequency reception or thermal fluctuation discernment. The ASRs record the information they gather, including streaming video from 360-degree cameras, and can transmit the data to oversight personnel or allow overseers to monitor circumstances live and communicate with people around the robot in real time through the ASRs speakers. “If you just look at the metrics, crime has a trillion-dollar negative economic impact on the U.S. every single year. It’s a hidden tax we all pay in blood, tears and treasure,” Santana Li said. The company’s K1 stationary robot, its mobile indoor K3 model and its outdoor patrolling K5 provide a deterrent to crime simply by being present 24 hours a day, every day of the year, according to Knightscope. The robots can even serve as a safety barrier against the pandemic’s virus transmission, responding to property visitors before human interaction takes place. They also recharge their own batteries at a nearby station when power levels drop significantly, keeping them on the job and economically priced in comparison to potential human staffing costs for the same measure of service. Santana Li noted that self-driving automobiles have received the lion’s share of attention over autonomous robotic technology, but said that in building the company he felt passionately that such endeavors were not the proper way to commercialize the technology, despite his background in the automotive industry. Years after investors began pouring millions of dollars into the automobile applications, real world users are still few and far between because of the need to not only master the technology, but the real world metrics of community safety for vehicles traveling at road speeds. Knightscope’s robots, on the other hand, travel at 1 to 3 mph and serve a specific need for private companies and government clients with little or no threat of erroneously causing harm themselves. “How many people in the audience did a transport or moved something or moved themselves this week in an autonomous vehicle? Nobody, right? So $80 billion went into the sector, nobody shipped anything that’s commercially viable,” Santana Li said. “I believe Knightscope’s the only company in the world operating 24/7, 365 (days) across an entire nation, fully autonomous, no human intervention, with real-world clients and real-world environments.” Knightscope received favorable attention from the market analysts at Mordor Intelligence, who cited the K5’s usefulness as a sign that the industry’s technology is evolving. Mordor forecasts a global market for ASRs reaching $3.91 billion by 2026, indicating it expects such platforms to increase in popularity with a CAGR of 7.93 percent between now and then (https://ibn.fm/KzblF). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• XPhyto Therapeutics Corp. plans to commercialize its rapid and portable PCR Kit this year to provide point-of-care diagnostics
• The company is confident about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021
• Hugh Rogers, CEO and Director of XPhyto, revealed in the latest news release that the company will make investments and development of psychedelic treatments

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator involved in the development of new pharmaceuticals, diagnostic products, and psychedelic medicine.

As a part of its business strategy for the year 2021, the company plans to commercialize its rapid PCR kit, “the one internationally recognized standard for testing Covid-19.” This announcement was made on January 18, 2021, when the company outlined its business strategy for 2021.

XPhyto’s rapid PCR diagnostic kit, secured through a strategic German alliance with 3a-diagnostics GmbH (“3a”), is a low-cost disposable kit with a turnaround time of fewer than 30 minutes. XPhyto is positive about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021 (https://ibn.fm/cJpDM).

Why is a Rapid Testing Kit critical in controlling the COVID pandemic?

With vaccines rolling out sporadically, a rapid definitive kit could play a pivotal role in 2021 to bring the pandemic under control. PCR kits are reliable and accurate tests for Covid-19 diagnosis.

XPhyto’s quick-turnaround time makes this PCR kit well-suited for mobile and pop-up labs. It is very important as the main hurdle for covid-19 testing is the long turnaround time that ranges from 4 hours to a few weeks.

This innovation is expected to be welcomed by the government and the healthcare providers who struggle with the bottlenecks of difficult diagnostic procedures (https://ibn.fm/Irm4I).

In the same news release, Hugh Rogers, CEO and Director of XPhyto, stated that the company is geared to make continued investments and development in the arena of psychedelic medicine.

As per the statistics from the US Center for Disease Control (“CDC”), 11% of Americans have contemplated suicide since the Covid-19 outbreak. Millions of Americans and Europeans are suffering from anxiety and mental illnesses, especially amidst the coronavirus outbreak. This phenomenon has expedited the development of psychedelic compounds for the formulation of mood-improving therapeutic pharmaceutical drugs (https://ibn.fm/Uk8aW).

Professor Löbenberg, a reputed scientist and director of XPhyto Therapeutics Corp holds Health Canada licenses for research and analytical testing of a wide range of psychedelic compounds, including molecules like LSD, psilocybin, and MDMA.

In addition to Dr. Löbenberg’s drug development experience, XPhyto’s German subsidiary –Vektor Pharma TF GmbH – has globally recognized drug delivery technology and manufacturing capabilities. Prof. Dr. Thomas Beckert, managing director of Vektor Pharma TF GmbH stated that the year 2021 will be pivotal for Vektor as the company will establish itself for commercial manufacturing, pipeline development, and drug formulations for critical mental health conditions (https://ibn.fm/hhgxP).

The market intelligence firm, Data Bridge Market Research, estimated that the psychedelic pharma market could grow to almost US $7bn by 2027 (https://ibn.fm/YF7Md). Another noted Canadian investment bank, Canaccord Genuity, estimates that the budding psychedelic industry will go on to be worth US $100bn. Companies like XPhyto Therapeutics enjoy an early-mover advantage that will give an edge over business opportunities among competitors within this science-driven psychedelic era.

For a full report on XPhyto’s research and innovation for Psychedelic drugs, read the article https://ibn.fm/4WlM0.

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at  https://ibn.fm/XPHYF

• Pure Extract Technologies pursues study into psilocybin active treatments
• Study to extend for 250-day period, targeting a number of milestones
• The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor
• Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, a potential legislative movement which may soon be replicated in other jurisdictions

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has provided investors with an update in regards to its ongoing study on the formulation and manufacturing of psilocybin-based active treatments through the provision of oral tablets and capsules, as well as a nasal gel which is set to be used as an investigational product (https://ibn.fm/p8GT0).

The study, which is being carried out according to Canadian Good Manufacturing Practice as well as Good Clinical Practice, is set to focus on the formulation, manufacturing and clinical bioavailability testing of rapid onset psilocybin forms – with the latter set to be used in future efficacy clinical trials carried out by both Pure Extracts and its pharmaceutical customers.

The Company has revealed that the research study, which will extend for a 250-day period, will pursue a number of milestones, including:

• Sourcing and procurement of medicinal ingredients, excipients & packaging materials
• Raw Material Testing
• Formulation and Manufacturing Process Development, Stability Testing
• Clinical Batch Manufacturing
• Quality Control Release Testing
• Shipping of Clinical Batches to CRO

The study is scheduled to be carried out at the Toronto Institute of Pharmaceutical Technology (“TIPT”) and is set to be overseen by Dr. Alexander MacGregor, a pharmaceutical science inventor and expert in the field of pharmaceutical technology and novel drug delivery systems. Dr MacGregor has successfully applied for a wide variety of global patents in the field of medical treatments and pharmaceutical drug delivery technologies, with his various innovations resulting in ground-breaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections and post-operative pain.

“We are excited about the R&D progress we are going to make with TIPT over the next 6 – 8 months while waiting to receive our Dealer’s License from Health Canada,” commented Pure Extracts’ CEO Ben Nikolaevsky regarding the study and tie-up with the TIPT. “We will be well prepared for our move into the controlled substances world of psychedelics and will have advanced knowledge regarding psilocybin and its associated novel delivery mechanisms.”

While psychedelics continue to be classified as a controlled substance in Canada, officials in the Canadian Government stated in November of 2020 – in response to an earlier petition tabled in Parliament – that there were still avenues whereby certain individuals could gain exemptions to legally consume them.

The group behind the petition, the Canadian Psychedelic Association (https://ibn.fm/fDyBC), said when the petition was originally read before Parliament in September that entheogenic medicines “could be the crucial missing piece in healing epidemic rates of depression, anxiety, PTSD, and drug addiction while empowering people to realize greater wholeness, purpose and connection.”

Nonetheless, the Canadian Government’s statement came only shortly after U.S. voters approved a measure to decriminalize the possession of plant-and fungi-based entheogenic substances, while voters in Oregon went further still – passing a reform initiative seeking to legalize psilocybin mushrooms for therapeutic use (https://ibn.fm/K3mqh).

Through its ongoing study delving into psilocybin based active treatments, Pure Extracts is now seeking to be at the very forefront of the product development curve should Canadian governmental authorities opt to legalize the use of psychedelics and psilocybin mushrooms in the coming future.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• As host to B. Riley’s Securities’ 2021 Vision Day, SRAX offers event content to Sequire community
• SRAX CEO states that B. Riley event is “perfect example of our growing Virtual Event Platform capabilities”
• Definitive agreement between SRAX-created BIGtoken, FPVD closes

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, concluded its role as the exclusive technology host for B. Riley Securities’ 2021 Vision Day (https://ibn.fm/D7R3c); sessions from the event are available exclusively to B. Riley clients and investors on the Sequire platform. The company also announced that its BIGtoken platform closed on its share exchange agreement with Force Protection Video Equipment Corporation (OTC: FPVD), making BIG a public company through the reverse merger transaction (https://ibn.fm/ir6ii). The prestigious B. Riley Vision Day event was held on the Sequire Virtual Events platform, thereby allowing the Sequire community privileged access to sessions and content. The daylong virtual investor conference included video presentations and fireside chats discussing the top stock picks from B. Riley’s award-winning equity research team. All the sessions are available exclusively to B. Riley clients and investors who register at BRiley.mysequire.com. “We were honored to have been selected by B. Riley Securities to host its 2021 Vision Day event, following our success with the LD Micro Main Event in December,” said SRAX founder and CEO Christopher Miglino. “This event is a perfect example of our growing Virtual Event Platform capabilities. We were pleased to work with the B. Riley team and contribute to another successful event. Other big news for SRAX is the closing of the previously announced share exchange transaction between SRAX-created BIGtoken and Force Protection Video Equipment Corporation (OTC: FPVD). Initially announced on Sept. 30, 2020, the definite agreement outlined plans for SRAX to receive 88.9% of the issued and outstanding shares of FPVD in exchange for 100% of the shares of BIGtoken. The agreement also noted that upon completion of the transaction, FPVD would be renamed BIGtoken with Lou Kerner appointed CEO (https://ibn.fm/Z2Sa3). “Lou has been working with data and internet startups his entire career,” said Miglino. “He has a detailed understanding of Blockchain and how it is applied to augment business applications. Blockchain will play a big part in the future of consumer identity and privacy, and we have a shared vision with Lou on what this will look like. Not only is Lou a technology expert, but his knowledge of the capital markets will be a significant asset to BIGtoken as the company is uplisted to a nationally listed exchange.” SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 3 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Most recent tests show MustGrow’s patented biopesticide achieved 100% control over Aphanomyces within 24 hours
• Plant-based biopesticide uses natural defense mechanism found in mustard seed to control diseases, pests and weeds
• MustGrow hoping to provide valuable crop-protection tool for pulse-crop farmers

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide has achieved 100% control of root-rot disease in a recent round of laboratory tests (https://ibn.fm/WJo4p). MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, is focused on providing natural, science-based biological solutions to replace synthetic chemicals in the cultivation process. MustGrow’s safe and effective organic biopesticide is plant based; it uses a natural defense mechanism found in the mustard seed to control diseases, pests and weeds. In a recent round of tests, which were conducted by an independent third-party lab, MustGrow’s patented mustard-derived biopesticide achieved 100% control over Aphanomyces euteiches zoospores (Aphanomyces) within 24 hours and at economic application rates. “It is great to see MustGrow’s mustard plant-based biopesticide continue to perform, particularly with 100% disease control measured at exceptionally low application rates,” said MustGrow COO Colin Bletsky. “The level of control of hard-to-kill diseases we continue to achieve combined with the beneficial properties of our product for soil health provide a great opportunity for improved yields for farmers and a more robust food supply. I am very hopeful that we can potentially provide a valuable crop-protection tool for pulse crop farmers.” Aphanomyces is a soil-borne, root-rot disease that destroys peas, lentils and legume crops, commonly referred to as pulse crops. In infected fields, the disease can result in yield losses ranging from 10% to 100% complete destruction. The ability to control the disease using an organic, plant-based biopesticide could have a significant impact on the harvests of farmers seeking to eradicate the disease. For instance, in 2019 Canada produced 9.2 million tons of pulse crops, making it one of the world’s largest producers. One study reported that Aphanomyces caused $20 million in annual pulse crop losses in Canada and $100 million worldwide. Currently the only available treatments slow down the spread in an attempt to reduce the severity of the disease; no treatments exist that control the devastating root-rot plague. MustGrow’s plant-based biopesticide aims to change that. With the most recent lab results in, MustGrow is now looking forward to evaluating its proprietary product in larger-scale greenhouse and field tests. MustGrow’s biopesticide is applied to the soil before crops are planted. The greenhouse and field tests are a significant step forward in the progression and preparation of the product for commercial use and application. This agriculture biotech company, which is focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, appears poised to leverage the growing momentum favoring alternatives to synthetic chemicals. As global agriculture looks to move closer to sustainable ways of boosting yields and crop protection, MustGrow continues to position itself as an essential part of the food landscape of the future with its mustard plant-based biopesticide. For more information, visit the company’s website at www.MustGrow.ca. NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Customers seek out highly personalized buying experiences in 2020 and beyond.
• Companies looking at what it means to be customer centric, how to create long-lasting relationships.
• Highly personalized customer service has always been high priority for SHRG.

As a new year begins, direct-selling leaders are looking to the future and wondering what trends will stick following the COVID-19 pandemic. Industry experts predict that companies with a strong customer-centric focus will perform the best moving forward, a prediction that bodes well for Sharing Services Global Corporation (OTCQB: SHRG). Sharing Services is committed to elevating the convenience and value of doing business for both its growing customer base and dedicated distributors. “The organizations that will perform the best through this period and beyond will be those that maintain a strong customer-centric focus while dealing with the complexity, uncertainty and risk that cloud the business landscape,” reported a recent “Direct-Selling News” article (https://ibn.fm/dEGMv). “This means knowing the sources of risk and opportunity within the global customer base. It means finding new routes to reaching customers—increasingly, through channels that customers control. And it means focusing less on driving customer transactions for short-term gain, and more on fostering trust-based relationships over the long term.” With that in mind, many companies are looking closely at what it means to be customer centric and how to create long-lasting relationships rather than short-term transactions. The rise of using digital tools instead of in-person sales was a necessity during the pandemic, but a convenience that may just stick around. Customers are seeking out tools that personalize their experience online. Add to this the rise of a gig economy, and the direct sales industry is experiencing massive growth. These are all priorities — and areas of expertise — for Sharing Services. SHRG markets and distributes health and wellness products under the Elevacity brand through an independent sales force of distributors called Elepreneurs. The company is committed to elevating customers’ and distributors’ lives through products, services and training opportunities. Sharing Services’ opportunity features a complete virtual business, including a phone app, web system and automated free sampling program — all designed to make it easier than ever before for SHRG Elepreneurs to focus on consumers. Customer centrism begins at home, observes the “Direct-Selling News” article. It starts on the front line with the distributors. Once the home front understands the value proposition of the company, sharing that message becomes second nature. SHRG executives have long credited the company’s success to its Elepreneurs, who are on the frontlines of the company and who continue to generate 100% organic growth. Through these entrepreneurs’ dedication to providing personalized customer experiences, customer retention has increased and capturing new markets has been achievable. Sharing Services Global Corporation is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Sharing Services has two primary divisions: Elevacity(R) Holdings LLC, the parent company of Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC, the parent company of wholly owned subsidiary Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line. For more information, visit the company’s website at www.SHRGInc.com NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas
• Glioblastomas are a class of aggressive brain cancers with no known cure and a median life expectancy of 14 to 16 months following diagnosis
• The FDA’s decision to grant CNSP’s request for IND status clears the way for the company to begin human clinical trials within the next couple of months
• The company’s sublicensee partner, WPD Pharmaceuticals, will also prepare a first-ever Phase I trial for drug safety in children, planned later this year in Poland

During the last year the COVID-19 pandemic has occupied large headlines worldwide while small neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) has been quietly building a newsworthy effort of its own to improve a select group of individuals’ lives, preparing to launch medical trials that could help end the unrelenting and ultimately fatal advance of glioblastoma brain cancers. CNSP acquired the worldwide exclusive licensing to its leading drug candidate Berubicin, an anthracycline that has demonstrated its potential in fighting off glioblastomas and a stand-out drug among other anthracyclines because of its apparent ability to effectively cross the blood-brain barrier and target central nervous system malignancies. In a January podcast interview, company CEO John Climaco showed his excitement at news the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status, clearing the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials. … We have five employees at this company, so we are a tiny little shop. But we have an absolute powerhouse compound.” The podcast, co-hosted by Sid Vaidya and Eric Gershey, is available for on-demand listening at https://anchor.fm/c3chat. Berubicin’s “powerhouse” potential was demonstrated in an initial Phase 1 trial completed by another company well over a decade ago. Within the very limited pool of participants in the trial, 44 percent saw their disease stabilize or even begin to improve. One patient emerged cancer-free and as of the most recent medical assessment last year was still alive and still in remission 14 years after the Phase 1 trial — a remarkable exception to the rule that the vast majority of glioblastoma patients will be dead within 14 to 16 months of diagnosis. CNSP’s planned Phase 2 trials will use a much larger pool of 243 patients for its real-time comparison of Berubicin’s performance against the “standard of care” chemotherapy drug lomustine in side-by-side brackets that compare the 162 Berubicin users with 81 lomustine users. The trials will take place in about 60 research centers scattered across North America, Europe and the Asia-Pacific region to help deliver a diverse representation of individuals (https://ibn.fm/4sWQi). While the adult trials are taking place, CNSP’s sublicensee partner for testing will also be preparing a first-ever Phase I trial for drug safety in children who have glioblastomas and have already failed to see a significant turnaround with standard-of-care medications. The pediatric trial is slated to begin later in the year in Poland. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Canada’s Clean Power Capital Corp., a holding company focused on investing in the renewable energy sector, recently increased its equity interest in California’s PowerTap Hydrogen Fueling Corp. from 90 percent to 94.5 percent
• PowerTap inked an agreement last month with the companies collectively comprising the Andretti Group, operated by auto racing legends Mario and Michael Andretti to situate and market PowerTap’s hydrogen fueling technology
• PowerTap followed up on the agreement by appointing Michael Andretti to the company board
• PowerTap recently announced the strategy behind its business model, focusing on profit motivations for the retail locations where the fueling stations will be located and PowerTap’s opportunities to expand without land lease expenses
• North America is undergoing a renewed interest in renewable energy sources under the administration of new U.S. President Joe Biden and Canada’s Prime Minister Justin Trudeau

PowerTap Hydrogen Fueling Corp., a majority-owned investee interest of investment issuer Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), is stepping up its dedication to clean energy infrastructure through cost-effective hydrogen fuel IP, modular fuel station product design flexibility and a launch plan for building a fueling network across California and into the rest of the nation.

PowerTap recently announced the appointment of auto racing legend Michael Andretti to its board following its January agreement with the businesses collectively known as the Andretti Group to install its 1,250-kilogram hydrogen production and dispensing stations at certain Andretti properties and to further market the stations to Andretti’s deep network of outside oil companies, chain retailers, cardlock operators and independent fueling stations.

The Andretti Group family of companies includes more than 100 retail chain stores focused on fuel, convenience and food operations. It runs or supplies facilities under the Chevron, Texaco, Shell, 76, Circle K, Pacific Pride and CFN brands, among others, throughout California, Oregon and Washington, according to the news release (https://ibn.fm/GI9vP).

PowerTap and the Andretti Group released further details on Feb. 8 regarding their strategic business model for the fueling stations and the ways PowerTap and retailers will benefit from the operation. Key points include using sites where the retailer can provide PowerTap with the necessary land for its modular hydrogen production and dispensing units without the need for lease expense to PowerTap and the retailer generates a profit from fuel sales by traditional methods, while PowerTap installs and maintains the units.

While the retailer is able to benefit from new traffic and find a new use for under-utilized land, PowerTap is able to operate its units without land expenses and is able to offer its customers the amenities inherent in existing fuel retail sites, leveraging the expertise of the Andretti Group’s affiliates.

“This exciting win-win relationship between PowerTap and the Andretti Group along with their industry partners will accelerate the deployment of our proprietary patented hydrogen production and dispensing technology, and provide a particularly compelling revenue share model with mutual benefit for all partners,” Incoming PowerTap President Salim Rahemtulla stated in the company’s announcement (https://ibn.fm/FRjnR).

North America’s renewed commitment to pursue “clean energy” through sources such as hydrogen fuel, as demonstrated by new U.S. President Joe Biden’s executive orders driving the country toward a carbon pollution-free power sector by 2035 (https://ibn.fm/jAXDY), coupled with Canada’s recently announced hydrogen strategy for building a net-zero carbon emissions infrastructure within the next three decades (https://ibn.fm/fZDVN) and Prime Minister Justin Trudeau’s acknowledgement that the two countries are poised to become collaborative partners in the clean energy supply chain (https://ibn.fm/cbl43), are further cause for excitement at PowerTap and Clean Power Capital.

PowerTap’s hydrogen-based technology is already being utilized at some hydrogen stations located at private and public sites in California, Texas, Massachusetts and Maryland. Clean Power announced Feb. 8 that it has increased its investment in PowerTap from a 90 percent equity interest to 94.5 percent as the Andretti agreements continue to build momentum (https://ibn.fm/LFkpy).

Clean Power holds 10 investments in varied sectors but restructured its corporate investment policy last year to focus on renewable energy. The company successfully held nearly $120 million in investments during 2020.The consideration paid for the additional 4.5 percent of PowerTap this year consisted of an aggregate of 18 million common shares in the capital of the company at a value of $2.72 per consideration share. The vendors have an arms-length relationship to each other and none of them individually owns more than 10 percent of the company’s shares on a non-diluted basis.

Clean Power is listed on the Canadian Securities Exchange’s CSE Composite Index (R) and the CSE25 (TM) index, and the company announced in December that it has formed a strategic committee to examine the possibility of listing common shares on the NASDAQ exchange in the United States (https://ibn.fm/2f2Yl).

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• Grapefruit expands availability of patented Hourglass by Grapefruit(TM) product to Greater Los Angeles area
• Hourglass is manufactured only at Grapefruit’s Coachillin facility, available only through Grapefruit authorized retailers
• GPFT achieved robust growth in 2020, poised to continue momentum going forward as demand remains strong

Grapefruit USA (OTCQB: GPFT), a premier fully licensed California-based company, has announced that its patented Hourglass time-release THC+Cannabinoid infused topical delivery cream has been rolled out to additional licensed retail cannabis locations in the Greater Los Angeles area (https://ibn.fm/ZohgC). Hourglass is manufactured exclusively at Grapefruit’s Coachillin facility and available only through Grapefruit authorized retailers. The company has announced that it will provide retail outlet locations as they come online in February as it continues to rapidly expand the number of California retailers that will carry the breakout Hourglass topical cream in the retail market. One of the recent additions includes licensed retail cannabis locations in Greater Los Angeles, California. Since the end of last year, Hourglass has been available to the public at Apothecary420, a well-respected dispensary located in Sherman Oaks, a suburb of Los Angeles. The company appears focused on rapid expansion as it continues to strengthen its premier brand recognized for high-quality products. In a recent update, the company announced recent developments concerning its patented Hourglass time-release THC+Cannabinoid delivery cream, reporting steady growth in market capitalization trading volumes. GPFT’s market capitalization grew from $11,809,990 on July 27, 2020, when the first major Hourglass project was announced to $30,282,026 at close on Jan. 15, 2021. Trading volume swelled over the same period, reflecting a robust investors’ demand (https://ibn.fm/k5J5m). But the company will not stop there. GPFT believes it can significantly improve this performance by the end of this year as the company grows other divisions and Hourglass capitalizes on the rise in demand for these unique products. Managed by a team of experts with relevant experience and skills to succeed in the competitive marketplace, GPFT leverages cutting-edge science and technology to deliver patented, truly disruptive products transforming the way consumers use the products. For more information, visit the company’s website at www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT